BIOTRONIK Launches its Pulsar-18 T3 Self-Expanding Stent System in the U.S. LAKE OSWEGO, Ore., July 26, 2022 /PRNewswire/ — BIOTRONIK, LAKE OSWEGO, USA, announced that it received U.S. Food and Drug Administration (FDA) approval of its innovative Pulsar®-18 T3 peripheral self-expanding stent system for an improved implantation procedure for endovascular treatments. The company also announced the full U.S. commercial […]
Author: Ken Dropiewski
Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer
BOSTON, July 26, 2022 /PRNewswire/ — Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development […]
Qardio+ Launches to Add New Level of Convenience to QardioArm Users
The new subscription service takes home health monitoring to the next level. SAN FRANCISCO, July 26, 2022 /PRNewswire/ — Qardio, a leader in connected care with predictive insight for a changing world, announces today the launch of their new subscription service Qardio+. Qardio+ will work with the QardioArm portable blood pressure monitor […]
New Zealand Endovascular Thought Leader Joins the VESTECK Scientific Advisory Board
WEST CHESTER, Pa., July 26, 2022 /PRNewswire/ — VESTECK, Inc. is pleased to announce that, international thought leader, Professor Andrew Holden has graciously agreed to join the VESTECK Scientific Advisory Board (SAB). A New Zealander, Professor Holden is currently the Director of Northern Region Interventional Radiology Service and is based at Auckland City Hospital. […]
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial. The approval expands the number of patients eligible for treatment […]
Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models
BEDFORD, Mass., July 26, 2022 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluatedi the […]
Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting
— Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease– — Small-diameter HAV observed to maintain patency and exhibit host-cell remodeling at six months post-implantation in a non-human primate model– –Results presented at American Heart Association Basic Cardiovascular Sciences Scientific Sessions 2022 […]
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent a diverse group of internationally renowned experts who will bring a depth and breadth of basic, translational, and clinical research […]
Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA
The Finkelstein-Schoenfeld Method of Win Ratios Analysis Provides New Insights Into Superiority of Ultrafiltration over Diuretics in Treating Fluid Overloaded Heart Failure Patients Resistant to Diuretics MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) a commercial-stage company focused on improving the quality of life for people with fluid overload, […]
InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation
Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pick” in Circulation: Arrhythmia and Electrophysiology SAN FRANCISCO, July 26, 2022 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing inhaled therapies […]



